114 related articles for article (PubMed ID: 32776743)
1. Study of Circulating Natural Antibodies Against CD25 and FOXP3 in Type-2 Diabetes.
Qiu C; Li C; Wu X; Chen X; Zhang X; Meng Q
Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776743
[TBL] [Abstract][Full Text] [Related]
2. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
Du KL; Ji WT; Jiang QH; Wang Y
Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
[TBL] [Abstract][Full Text] [Related]
3. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
4. Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma.
Wang J; Xu Y; Wang Y; Zhang X; Zhang G
Onco Targets Ther; 2019; 12():10487-10493. PubMed ID: 31819529
[TBL] [Abstract][Full Text] [Related]
5. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
Wang J; Xu Y; Zhao H; Zhang X
J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
Liu S; Zhang X; Jiang Q; Liang T
FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
[TBL] [Abstract][Full Text] [Related]
7. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
[TBL] [Abstract][Full Text] [Related]
8. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
[TBL] [Abstract][Full Text] [Related]
9. CD4
Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
[TBL] [Abstract][Full Text] [Related]
10. Critical stoichiometric ratio of CD4(+) CD25(+) FoxP3(+) regulatory T cells and CD4(+) CD25(-) responder T cells influence immunosuppression in patients with B-cell acute lymphoblastic leukaemia.
Bhattacharya K; Chandra S; Mandal C
Immunology; 2014 May; 142(1):124-39. PubMed ID: 24354800
[TBL] [Abstract][Full Text] [Related]
11. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
Brusko T; Wasserfall C; McGrail K; Schatz R; Viener HL; Schatz D; Haller M; Rockell J; Gottlieb P; Clare-Salzler M; Atkinson M
Diabetes; 2007 Mar; 56(3):604-12. PubMed ID: 17327427
[TBL] [Abstract][Full Text] [Related]
12. Role of regulatory CD4+CD25+ Foxp3 T cells in bronchial asthma in Egyptian children.
Bakr SI; Mahran MZ; Soliman DA
Egypt J Immunol; 2013; 20(2):29-38. PubMed ID: 24617045
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance.
Cai W; Qiu C; Zhang H; Chen X; Zhang X; Meng Q; Wei J
J Inflamm (Lond); 2017; 14():24. PubMed ID: 29142506
[TBL] [Abstract][Full Text] [Related]
14. Expression of Th17 and CD4
Xiang M; Guo L; Ma Y; Li Y
Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2405-2410. PubMed ID: 28167485
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants.
Barreto M; Ferreira RC; Lourenço L; Moraes-Fontes MF; Santos E; Alves M; Carvalho C; Martins B; Andreia R; Viana JF; Vasconcelos C; Mota-Vieira L; Ferreira C; Demengeot J; Vicente AM
BMC Immunol; 2009 Jan; 10():5. PubMed ID: 19173720
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients.
Yuan N; Zhang HF; Wei Q; Wang P; Guo WY
Exp Clin Endocrinol Diabetes; 2018 Feb; 126(2):96-101. PubMed ID: 28954308
[TBL] [Abstract][Full Text] [Related]
17. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus.
Suen JL; Li HT; Jong YJ; Chiang BL; Yen JH
Immunology; 2009 Jun; 127(2):196-205. PubMed ID: 18800986
[TBL] [Abstract][Full Text] [Related]
18. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
19. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
20. In vivo depletion of CD4+CD25+ regulatory T cells in cats.
Smithberg SR; Fogle JE; Mexas AM; Reckling SK; Lankford SM; Tompkins MB; Dean GA
J Immunol Methods; 2008 Jan; 329(1-2):81-91. PubMed ID: 17980384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
